Literature DB >> 8267948

Low-dose angiotensin II increases glucose disposal rate during euglycemic hyperinsulinemia.

B R Widgren1, V Urbanavicius, J Wikstrand, S Attvall, B Persson.   

Abstract

To study the metabolic effects of angiotensin II we examined the glucose disposal rate and calf blood flow in healthy men (n = 39) during euglycemic hyperinsulinemia followed by a period with simultaneous angiotensin II infusion at a low dose (0.1 ng/kg/min). Angiotensin II infusion abruptly increased the glucose disposal rate significantly as compared with glucose disposal rate during euglycemic hyperinsulinemia only. There were no differences in blood glucose or plasma insulin between the euglycemic hyperinsulinemic and the angiotensin II infusion period. During hyperinsulinemia alone, blood pressure was unchanged while calf muscle blood flow increased significantly as compared with the baseline period, while during the angiotensin infusion the systolic blood pressure increased and calf blood flow decreased significantly as compared with the hyperinsulinemic period. We conclude that angiotensin II within physiological range stimulates insulin-mediated glucose uptake in healthy men. The mechanisms are, however, unclear, but changes in blood flow are probably not responsible for the observed effects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8267948     DOI: 10.1093/ajh/6.10.892

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  3 in total

Review 1.  Metabolic actions of angiotensin II and insulin: a microvascular endothelial balancing act.

Authors:  Ranganath Muniyappa; Sahzene Yavuz
Journal:  Mol Cell Endocrinol       Date:  2012-06-07       Impact factor: 4.102

Review 2.  The renin angiotensin aldosterone system and insulin resistance in humans.

Authors:  Patricia C Underwood; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

3.  Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: relationship to angiotensin-converting enzyme inhibition.

Authors:  R Reneland; P E Andersson; A Haenni; H Lithell
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.